ABL Bio is a biotech research company that focuses on the development of therapeutic drugs for immuno-oncology diseases.
ABL Bio has raised $3.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in September 2023.
ABL Bio's investors include Korea Investment Partners, IMM Investment, DSC Investment, DS Asset Management, QUAD Investment Management.
ABL Bio is headquartered in Seongnam, South Korea.
ABL Bio is a biotech research company that focuses on the development of therapeutic drugs for immuno-oncology diseases.
ABL Bio is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ABL Bio — Funding & Investors." VCBacked, September 7, 2023, https://www.vcbacked.co/company/abl-bio. Accessed July 19, 2026.
VCBacked. (2023). ABL Bio — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/abl-bio
{{cite web |title=ABL Bio — Funding & Investors |url=https://www.vcbacked.co/company/abl-bio |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated